Quentin LedfordThis is absolutely infuriating! Moreover, they really DON'T KNOW what are in these injections. The organization has NO business promoting this garbage. It is not even remotely related to our purpose.
We do know though, from those who have had these injectables analyzed that they do contain a lot of very unsavory and dangerous stuff.
Until this entire scamdemic ordeal, I wasn't particularly anti-vax.
However, knowing what we do now, there is NO way I would subject myself, or even my worst ... moreThis is absolutely infuriating! Moreover, they really DON'T KNOW what are in these injections. The organization has NO business promoting this garbage. It is not even remotely related to our purpose.
We do know though, from those who have had these injectables analyzed that they do contain a lot of very unsavory and dangerous stuff.
Until this entire scamdemic ordeal, I wasn't particularly anti-vax.
However, knowing what we do now, there is NO way I would subject myself, or even my worst enemy, with these death dealing poisons.
Moreover, ANY parent who allows their children to be vaccinated today is completely irresponsible and unknowingly cruel, acting solely out of the irrational phobia of pharmaceutical industry induced terror!!!
AdminThis is intended for infants before it was for 12 -18 years and over!
For the full list of side effects and restrictions with SPIKEVAX, see the package leaflet.
The most common side effects with Spikevax are usually mild or moderate and get better within a few days after vaccination. These include redness, pain and swelling at the injection site, TIREDNESS, chills, fever, SWOLLEN or TENDER LYMPH NODES UNDER THE ARM, headache, muscle and JOINT PAIN, nausea (feeling sick) and VOMITING. They may ... moreThis is intended for infants before it was for 12 -18 years and over!
For the full list of side effects and restrictions with SPIKEVAX, see the package leaflet.
The most common side effects with Spikevax are usually mild or moderate and get better within a few days after vaccination. These include redness, pain and swelling at the injection site, TIREDNESS, chills, fever, SWOLLEN or TENDER LYMPH NODES UNDER THE ARM, headache, muscle and JOINT PAIN, nausea (feeling sick) and VOMITING. They may affect more than 1 in 10 people. In infants under 3 years of age, irritability, crying, sleepiness and loss of appetite are also very common side effects (affecting more than 1 in 10 infants).
Hives and rash at the injection site, sometimes occurring more than a week after injection, rash affecting areas other than the injection site and diarrhoea may affect less than 1 in 10 people. Itching at the injection site, DIZZINESS and ABDOMINAL PAIN may affect less than 1 in 100 people. SWELLING OF THE FACE, which may affect people who had facial cosmetic injections in the past, weakness in muscles on one side of the face (acute peripheral facial paralysis or palsy), paraesthesia (unusual feeling in the skin, such as tingling or a crawling feeling) and hypoaesthesia (reduced sensation to touch, pain and temperature) may affect less than 1 in 1,000 people.
MYOCARDITIS (INFLAMMATION OF THE HEART MUSCLE) and PERICARDITIS (inflammation of the membrane around the heart) may occur in up to 1 in 10,000 people.
A very small number of cases of erythema multiforme (red patches on the skin with a dark red centre and paler red rings) have occurred. Allergic reactions have also occurred in people receiving the vaccine, including a very small number of cases of severe allergic reactions (ANAPHYLAXIS).
The safety of the adapted vaccines is comparable to that of the originally authorised Spikevax vaccine.
European Medicines Agency;
COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of
MYOCARDITIS and PERICARDITIS
Dear Healthcare professional,
BIONTECH/PFIZER and MODERNA BIOTECH SPAIN, S.L. in agreement with the
European Medicines Agency and <National competent authority> would like to
inform you of the following:
Summary
• Cases of myocarditis and pericarditis have been reported very
rarely following vaccination with the COVID-19 mRNA Vaccines
Comirnaty and Spikevax.
• The cases primarily occurred within 14 days after vaccination,
more often after the second dose and in younger men.
• Available data suggest that the course of myocarditis and
pericarditis following vaccination is similar to the course of
myocarditis and pericarditis in general.
• Healthcare professionals should be alert to the signs and
symptoms of myocarditis and pericarditis.
• HEALTHCARE PROFESSIONALS SHOULD ADVISE VACCINATED INDIVIDUALS to
seek immediate medical attention should they experience chest
PAIN, SHORTNESS OF BREATH, or PALPITATIONS.
Background on the safety concern
The COVID-19 mRNA vaccines, Comirnaty and Spikevax, have been
approved in the EU under conditional marketing authorisation for active
immunisation to prevent COVID-19 infection caused by SARS-CoV-2, in
individuals 12 years of age and older (Comirnaty) and 18 years of age and
older (Spikevax), respectively.
Myocarditis and pericarditis have been reported in association with the
COVID-19 mRNA vaccines.
The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment
Committee (PRAC) has evaluated all available data and concluded that a
causal association between COVID-19 mRNA vaccines and myocarditis and
pericarditis is at least a reasonable possibility.
This medicinal product is subject to ADDITIONAL MONITORING. This will allow quick identification of
new safety information. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
JCOVDEN suspension for injection
COVID-19 vaccine (Ad26.COV2-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
This is a multi-dose vial which cont... moreJcovden info from European Medicines Agency
This medicinal product is subject to ADDITIONAL MONITORING. This will allow quick identification of
new safety information. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
JCOVDEN suspension for injection
COVID-19 vaccine (Ad26.COV2-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
This is a multi-dose vial which contains 5 DOSES of 0.5 mL.
One dose (0.5 mL) contains:
ADENOVIRUS type 26 encoding the SARS-CoV-2 SPIKE GLYCOPROTEIN* (Ad26.COV2-S), not less than
8.92 log10 INFECTIOUS UNITS (Inf.U).
* Produced in the PER.C6 TetR CELL LINE and by RECOMBINANT DNA TECHNOLOGY.
The product contains GENETICALLY MODIFIED ORGANISMS (GMOs).
Excipients with known effect
Each dose (0.5 mL) contains approximately 2 mg of ETHANOL.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension for injection (injection).
Colourless to slightly yellow, clear to very opalescent suspension (pH 6-6.4).
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
JCOVDEN is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in
individuals 18 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
4.2 Posology and method of administration
Posology
Individuals 18 years of age and older
Primary vaccination
JCOVDEN is administered as a single-dose of 0.5 mL by intramuscular injection only.
Note PER C6 also in link below;
Comments: Derived from site: In situ; Fetal eye, retina; UBERON
Species of origin: Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children
Vaxzevria info from European Medicines Agency
This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
NEW SAFETY INFORMATION. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSIT... moreHow comes the org don't give these details..
Vaxzevria info from European Medicines Agency
This medicinal product is subject to ADDITIONAL monitoring. This will allow quick identification of
NEW SAFETY INFORMATION. Healthcare professionals are asked to report any SUSPECTED adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
These are MULTIDOSE vials which contain 8 DOSES or 10 DOSES of 0.5 ml per vial (see section 6.5).
One dose (0.5 ml) contains:
CHIMPANZEE ADENOVIRUS ENCODING the SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)
*
, not less than
2.5 × 108
infectious units (Inf.U)
*Produced in GENETICALLY MODIFIED HUMAN EMBRYONIC KIDNEY (HEK) 293 CELLS and by RECOMBINANT
DNA TECHNOLOGY.
This product contains GENETICALLY MODIFIED ORGANISMS (GMOs).
Excipient with known effect
Each dose (0.5 ml) contains approximately 2 mg of ETHANOL.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension for injection (injection).
The suspension is colourless to slightly brown, clear to slightly opaque with a pH of 6.6.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Vaxzevria is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in
individuals 18 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
Comments (14)